#United States #Nashville #Parkinson's Disease #Mitsubishi Tanabe #ND0612

Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced its participation in the upcoming 2024 Annual Meeting of the Parkinson Study Group (PSG), which is scheduled to be held from December 5 to December 8 in Nashville, Tennessee. The company will showcase two significant abstracts related to the experimental treatment ND0612, aimed at enhancing the management of Parkinson's disease (PD).

ND0612 represents an innovative approach to treating motor fluctuations in individuals suffering from Parkinson's Disease. This investigational treatment involves a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD), designed to provide a steadier delivery of medication compared to traditional methods. This could potentially lead to improved patient outcomes, as motor fluctuations are a common challenge faced by PD patients.

Dr. Gustavo A. Suarez Zambrano, Vice President of Medical Affairs at MTPA, voiced excitement about attending the PSG meeting, stating, “We look forward to attending the PSG meeting where we will discuss our latest findings on investigational ND0612 with other experts from the scientific community.” This underscores MTPA's commitment to addressing significant unmet needs in the Parkinson's community through ongoing research.

Presentation Highlights

MTPA’s presentations are set to take place in Grand Hall A, B, and C on December 5, from 5:00 PM to 7:00 PM CST. The key presentations will include:
1. Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 for Parkinson’s Disease: This presentation will cover data from the open-label, Phase 2b BeyoND study (NCT02726386), which thoroughly assessed the safety and efficacy of ND0612 over a three-year period among patients experiencing significant motor fluctuations.
2. Characterization of Infusion Site Reactions (ISRs): This session will detail the infusion site reactions reported during clinical studies, providing a clearer understanding of the treatment’s side effects and patient tolerance over the lengthy administration period.

These findings could play a crucial role in enhancing treatment regimens for Parkinson’s patients, as infusions could provide a more reliable mode for medication delivery, lowering peak-trough fluctuations that often lead to unpredictable symptoms.

About ND0612

ND0612 is not just a medication but a sophisticated drug-device combination therapy. The integration of continuous infusion technology with levodopa/carbidopa therapy marks a significant advancement in the treatment landscape for people with Parkinson's disease. NeuroDerm, Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, is spearheading the development of ND0612, emphasizing their commitment to innovative treatments for CNS disorders.

Company Background

Mitsubishi Tanabe Pharma America operates from Jersey City, New Jersey, with a focused mission to develop and commercialize pharmaceutical products throughout North America. Its parent company, Mitsubishi Tanabe Pharma Corporation, has a rich history dating back to 1678 and specializes in ethical pharmaceuticals. The organization is committed to pioneering solutions in various therapeutic areas including CNS diseases, cancer, and more.

As MTPA prepares for its presentations at the PSG meeting, the global audience can anticipate important updates that may reshape the understanding and treatment of Parkinson's disease, offering hope to countless patients and their families.

For more information, you can visit Mitsubishi Tanabe Pharma America or follow their updates on social media platforms.